eGenesis has raised $38M in Series A financing. The funding was led by Biomatics Capital and ARCH Venture Partners. Also participating were Khosla Ventures, Alta Partners, Alexandria Equities, Heritage Provider Network, Berggruen Holdings North America, Uprising, and Fan Ventures.

eGenesis is a life sciences company focused on leveraging CRISPR technology to deliver safe and effective human transplantable cells, tissues and organs to the hundreds of thousands of patients worldwide who are in dire need.